Dividend5 May 2026, 08:01 pm
Jenburkt Pharma Recommends ₹20.70 Dividend for FY26
AI Summary
Jenburkt Pharmaceuticals Ltd's Board of Directors has recommended a dividend of ₹20.70 (207%) per equity share of ₹10 each on 4413300 equity shares for the financial year 2025-26. The board also approved the standalone audited financial statements for the quarter and year ended March 31, 2026, and scheduled the 41st Annual General Meeting for September 4, 2026, via video conferencing. Additionally, Shri Dilip H. Bhuta was re-appointed as the Whole Time Director and CFO for five years, effective April 1, 2027.
Key Highlights
- Dividend of ₹20.70 (207%) per share recommended for FY26.
- Standalone audited financial statements for FY26 approved.
- 41st Annual General Meeting scheduled for September 4, 2026.
- Dilip H. Bhuta re-appointed as Whole Time Director and CFO.
- Auditors’ Report with unmodified opinion presented by D. R. Mehta & Associates.
Price Impact
More from JENBURPH*